文献速递神经肿瘤

患者来源胶质母细胞瘤肿瘤球预测治疗反应的临床价值

The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
PubMed 文献 · Neuro Oncol · 2017-01-01

该研究在52例接受手术切除后放疗和替莫唑胺治疗的胶质母细胞瘤中,探讨肿瘤球生长与临床结局的关系,并将肿瘤球对放疗和替莫唑胺的敏感性与患者生存关联。结果显示肿瘤球生成是总生存和无进展生存不良的独立因素,对替莫唑胺的敏感性与生存直接相关,半数抑制浓度<50 μM可识别生存更长的病例。

要点

  • 肿瘤球生成是胶质母细胞瘤总生存和无进展生存不良的独立因素(P<.0001和P=.0010)。
  • 肿瘤球对替莫唑胺的敏感性与患者总生存和无进展生存直接相关(P=.0167和P=.0436)。
  • 替莫唑胺半数抑制浓度<50 μM可识别总生存和无进展生存更长的病例(P=.0020和P=.0016)。

核心结论

  • 肿瘤球分析具有转化意义,可预测亲本肿瘤对放疗尤其是对替莫唑胺的反应。
  • 从肿瘤球中区分克隆形成群体与增殖后代可指导治疗策略,以实现更有效的药物选择和疗程确定。

研究设计与样本

  • 研究纳入52例接受手术切除后放疗和替莫唑胺治疗的胶质母细胞瘤,分析肿瘤球生长与临床结局的关系。
  • 将肿瘤球对放疗(6至60 Gy)和替莫唑胺(3.9 μM至1 mM)的效应与患者生存进行关联分析。

主要发现

  • 肿瘤球生成是总生存和无进展生存不良的独立因素(P<.0001和P=.0010)。
  • 肿瘤球的生长速率和克隆形成能力预测总生存不良。
  • 肿瘤球对放疗和替莫唑胺普遍高度耐药;克隆形成能力高且生长快的肿瘤球对替莫唑胺耐药更强(P<.02)。
  • 匹配肿瘤球的放疗LD50(杀死50%肿瘤球细胞所需致死剂量)>12 Gy与更短的无进展生存相关(P=.0484)。
  • 肿瘤球对替莫唑胺的敏感性与患者生存直接相关(总生存P=.0167,无进展生存P=.0436)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advances from glioma stemlike cell (GSC) research, though increasing our knowledge of glioblastoma (GBM) biology, do not influence clinical decisions yet. We explored the translational power of GSC-enriched cultures from patient-derived tumorspheres (TS) in predicting treatment response. METHODS: The relationship between TS growth and clinical outcome was investigated in 52 GBMs treated with surgical resection followed by radiotherapy and temozolomide (TMZ). The effect on TS of radiation (6 to 60 Gy) and of TMZ (3.9 μM to 1 mM) was related with patients' survival. RESULTS: Generation of TS was an independent factor for poor overall survival (OS) and poor progression-free survival (PFS) (P < .0001 and P = .0010, respectively). Growth rate and clonogenicity of TS predicted poor OS. In general, TS were highly resistant to both radiation and TMZ. Resistance to TMZ was stronger in TS with high clonogenicity and fast growth (P < .02). Shorter PFS was associated with radiation LD50 (lethal dose required to kill 50% of TS cells) >12 Gy of matched TS (P = .0484). A direct relationship was found between sensitivity of TS to TMZ and patients' survival (P = .0167 and P = .0436 for OS and PFS, respectively). Importantly, values for TMZ half-maximal inhibitory concentration <50 μM, which are in the range of plasma levels achieved in vivo, identified cases with longer OS and PFS (P = .0020 and P = .0016, respectively). CONCLUSIONS: Analysis of TS holds translational relevance by predicting the response of parent tumors to radiation and, particularly, to TMZ. Dissecting the clonogenic population from proliferating progeny in TS can guide therapeutic strategies to a more effective drug selection and treatment duration.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. D'Alessandris QG, Biffoni M, Martini M, et al. The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. Neuro Oncol. 2017. PMID: 28204560. doi:10.1093/neuonc/now304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。